The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential SynergiesLeisha A. Emens, Gary Middleton|Cancer Immunology Research|2015Cited by 814
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysisLeisha A. Emens, P. Schmid|Annals of Oncology|2021Cited by 453
Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130H. S. Rugo, Leisha A. Emens, Sylvia Adams et al.|Annals of Oncology|2019Cited by 115